Unshackling caspase-7 for cancer therapy

Maria Eugenia Guicciardi, Gregory J. Gores

Research output: Contribution to journalComment/debatepeer-review

6 Scopus citations


Numerous solid tumors and hematologic malignancies acquire resistance to apoptosis-inducing chemotherapeutic drugs by downregulating the key effector caspase-3. These cells rely on caspase-7 to execute the apoptotic program, yet binding with XIAP constitutively inhibits active caspase-7 (p19/p12-CASP7). In this issue, Lin et al. describe how a newly synthesized drug is able to disrupt the XIAP:p19/p12-CASP7 complex and induce apoptosis in caspase-3-deficient cancer cells in vitro and in vivo. As this compound appears to exhibit minimal toxicity on normal tissues, it may represent a promising therapeutic agent to help treat caspase-3-deficient tumors.

Original languageEnglish (US)
Pages (from-to)3706-3708
Number of pages3
JournalJournal of Clinical Investigation
Issue number9
StatePublished - Sep 3 2013

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Unshackling caspase-7 for cancer therapy'. Together they form a unique fingerprint.

Cite this